tPA alone

Phase 3Biologic

CChildren's Mercy Hospital Kansas City

tPA alone is one of 6 biologic programs targeting Empyema. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EmpyemaActive, not recruiting

EmpyemaPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Empyema

#DrugCompanyPhaseTrials

Betadine

BBecton, Dickinson and Company

Activase

1 3

Urokinase

Mmedac GmbH

Phase 3

1 4

Tpa

UUniversity of Florida

Phase 3

1 5

tPA alone

CChildren's Mercy Hospital Kansas City

Phase 3

1 6

Dnase

TThe Hospital for Sick Children

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Empyema1 trial

Empyema Treated With tPA & DNAse

Withdrawn·—·Phase 3·NCT01862458

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for tPA alone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tPA alone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tPA alone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Children's Mercy Hospital Kansas City company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CChildren's Mercy Hospital Kansas City

tPA alone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Empyema1 trial

References

Drug Info

Quick Facts

Related News